Side-by-side comparison of AI visibility scores, market position, and capabilities
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
US AI healthcare scheduling agent for hospitals replacing complex manual shift management; Rippling-for-healthcare vision with optimization algorithms and agentic AI targeting nursing staff scheduling competing with Kronos and UKG Workforce.
YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the complex, administrator-dependent scheduling software that hospitals currently use. Founded to address the operational inefficiency at the intersection of clinical workforce management and scheduling complexity, YouShift applies optimization algorithms and agentic AI to generate shift schedules that simultaneously respect hospital staffing requirements (coverage ratios, certification requirements, department-specific rules) and staff preferences (requested days off, preferred shift patterns, commute constraints) — eliminating the manual schedule-building work that currently requires full-time administrative staff at most hospital systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.